Intraosseous Devices Market Size, Share and Global Trend By Device Type(Manual Semi-automated, Automated), By Location (Sternum, Distal Femur, Distal & Proximal Tibia, Calcaneus, Head of Humerus, Non-viral vectors), By Age Group (Adults, Pediatrics), By End User(Hospital, Emergency Medicine, Ambulatory Surgical Centers, Specialty Clinics, Trauma Centers Regional Forecast, 2024-2032

Immediate vascular system access is a priority at times for life-threatening traumatic injuries for the quick delivery of medications and fluids. Intraosseous Devices are now being used for the same purpose in emergency medical conditions. Intraosseous infusion is a process of injecting medications and fluids directly into the bone marrow. They can be administered directly into the medullary canals in the manubrium of the sternum, tibia, and humerus. In intraosseous infusion, a needle is injected through the hard cortex of the bone into the interior soft marrow, allowing immediate access to the vascular system.

The Australian Resuscitation Council ALS guidelines advise the use of intraosseous devices in the event where I.V. access seems to be impossible for both adults and pediatrics. Such government recommendations and new product introduction are positively impacting the global intraosseous devices market. In February 2016, Pyng Medical, which is now acquired by Teleflex Incorporated, launched FASTTactical, a new device for sternal intraosseous infusion specially designed for military, Emergency Medical Services (EMS) and, hospital critical care teams, which is likely to support the global intraosseous devices market. 

Growth in Intraosseous Devices Market is driven by the increase in incidence of life-threatening traumatic injuries, increase in emergency cases needing immediate fluid resuscitation, increasing adoption of intraosseous devices by healthcare professionals, and emerging guidelines for intraosseous infusion at time of life-threatening emergencies. Since 2005, the American Heart Association (AHA) guidelines for CPR and ECC, have suggested the use of intraosseous devices as an alternative to intravenous (I.V.) administration of medications and fluids, which is expected to fuel the intraosseous devices market in the forecast period. 

On the contrary, complications associated with the use of intraosseous devices such as extravasation of fluids and medications into the soft tissue and fractures may lead to osteomyelitis, which is expected to inhibit the growth in intraosseous devices market. 

Key Players Covered 

Some of the major companies that are present in the global intraosseous devices market are PerSys Medical, Cook, Pyng Medical, Teleflex Incorporated, Aero Healthcare AU Pty Ltd., Becton, Dickinson and Company, PAVmed Inc., and other players 

SEGMENTATION 

Hospital segments are expected to have a major portion of the global intraosseous devices market, owing to the increase in a number of emergency visits for cardiac arrest cases, and large scale use of intraosseous devices during resuscitation and life-threatening injuries. 

Key Insights 

• Overview of intraosseous infusion guidelines
• Pricing analysis
• Regulatory scenario for key countries
• Key mergers and acquisitions
• Introduction of new products/approvals (by major players)  

Regional Analysis 

The global intraosseous devices market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the global intraosseous devices market during the projected period owing to the emerging guidelines, and new product launch. In 2019, PAVmed Inc. announced that PortIO Intraosseous Infusion System, an implantable intraosseous device under investigation, achieved maintenance-free successful implant period of around 60 days in pre-clinical animal testing. The expected marketing clearance of the product by the FDA is anticipated to accelerate the global intraosseous devices market in North America. In Europe and Asia Pacific, the global intraosseous devices market is estimated to expand in the forecast duration owing to the rising number of cardiac diseases and emergency visits.

Key Industry Developments

• In March 2019, PAVmed Inc., announced that PortIO Intraosseous Infusion System, an implantable intraosseous device under investigation, achieved maintenance-free successful implant period of around 60 days in pre-clinical animal testing
• In April 2017, Teleflex Incorporated acquired Pyng Medical, which resulted in acquisition of Pyng Medical’s product portfolio which included devices for intraosseous infusion
• In February 2016, Pyng Medical, which is now acquired by Teleflex Incorporated, launched FASTTactical, a new device for sternal intraosseous infusion specially designed for military, Emergency Medical Services (EMS) and, hospital critical care teams.